Phase II Trial of Rituximab In Myasthenia Gravis

Conditions

Diseases of the Nervous System

Phase II

What is the purpose of this trial?

The specific primary aim of this study is to determine whether rituximab is a safe and beneficial therapeutic for MG that warrants further study in a phase III efficacy trial. The main secondary objective is to evaluate whether there is a trend toward clinical benefit as measured by MG-specific clinical outcome scales. If successful, measures studied would lay the groundwork toward optimizing the design of a subsequent phase III fficacy trial of rituximab in MG.

  • Trial with
    National Institute of Neurological Disorders and Stroke (NINDS)
  • Start Date
    05/06/2014
  • End Date
    12/30/2015

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image

For more information about this study, contact:

Joan Nye

  • Last Updated
    02/22/2018
  • Study HIC
    #1401013253